Author:
Mohd Asngari Nurul Jannah,Bakar Khairul Azreena,Feroz Shevin,Razak Fathilah,Halim Adyani Azizah Abd
Reference51 articles.
1. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension;R Recker;J Bone Miner Res,2020
2. Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases;L Hao;J Periodontol,2015
3. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease;L Hao;Infect Immun,2015
4. Merck &Co. drops osteoporosis drug odanacatib;A Mullard;Nat Rev Drug Discov,2016
5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study;M R Mcclung;Lancet Diabetes Endocrinol,2019